Navigation Links
CBI Announces 13th Annual Patient Assistance and Access Programs
Date:1/9/2012

WOBURN, Mass., Jan. 9, 2012 /PRNewswire/ -- Advanstar|CBI recently announced the full agenda for their 13th Annual Patient Assistance and Access Programs. The Forum takes place March 6-7, 2012 in Baltimore, MD.

PAP's speaker faculty includes leading experts from Eli Lilly, Genentech, AstraZeneca, Shire Human Genetic Therapies and many more.

Patient Assistance Pavilion participant Needy Meds recently interviewed PAP's Senior Program Manager, Sharon Langan. During the interview, Langan delved into the details of the conference, including new speakers and highlights from the agenda, notably, a new Safety Net Resources Track, chaired by Needy Meds.

This Forum is the most robust and renowned meeting for executives engaged in pharmaceutical patient assistance and access programs. For more information on the conference or to view the entire agenda, please visit http://www.cbinet.com/pap.

About CBI:

CBI, a subsidiary of Advanstar, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. CBI's conferences provide a unique platform for concrete, real-life examples that can be applied to any organization immediately, significantly impacting both costs and revenue. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact Kristina Weljkovic, Marketing Manager, at 339-298-2285.

 

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE CBI
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
2. diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance
3. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. Sutro Announces Newly Formed Scientific Advisory Board
6. AnaptysBio Announces New Strategic Antibody Discovery
7. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
8. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
9. AtheroNova Announces a New Board Member
10. RSB Spine, LLC Announces 2011 Revenue Growth
11. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)...   Sienna Biopharmaceuticals, Inc. , a privately held, ... Richard Peterson will join the company as ... who brings more than two decades of global financial ... retiring at the end of April but will continue ... Sienna from Novan, Inc., where he served as Chief ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... New York , March 23, 2017 ... blood plasma products and derivatives market is fragmented due to the presence ... players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete ... leader, these three companies, collectively, held more than 76% of this ... ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
Breaking Biology News(10 mins):